Oral gefitinib plus methotrexate is not clinically superior to methotrexate for tubal ectopic pregnancy.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Oral gefitinib plus methotrexate is not clinically superior to methotrexate for tubal ectopic pregnancy.

Latest News

Democrats Press RFK Jr. on an Ethics Agreement Change Involving Law Firm Fees

Two Procedures May Yield Similar Symptom Relief for Uterine Fibroids

Maternal Tdap Blunts Preschoolers' Pertussis Shot Response, but Booster Revives Them

FDA Nominee Voices Support for Vaccines at Senate Hearing Scrutinizing Trump's Moves

Hereditary Insight: Navigating High- and Moderate-Risk Genes for Breast Cancer Treatment

Gauging Benefits of Risk-Reducing Surgery for BRCA-Related Ovarian Cancer

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Latest News

News All Time

U.S. Women Increasingly Not Screened for Cervical Cancer

These Women Face Higher Risk for Anal Sphincter Tears During Birth

Bictegravir-Lenacapavir Combo Pill Earns FDA Approval in Suppressed HIV

Her Breast MRI Was Approved, but That Didn't Mean Her Insurance Would Pay

Lionel Richie Hospitalized; CDC Challenges Measles Toll; Vitamin K Refusals Rise

Nurse Who Saved Baby in Pakistan Hospital Fire Wishes She Could Have Saved the Rest

Gloria Steinem on Women's Rights, Abortion Politics, and Being Called the B-Word

Judge Declares Mistrial in Lindsay Clancy Case

Judge Sends Deadlocked Lindsay Clancy Jurors Home

One of the Lindsay Clancy Trial's Most Instructive Moments for Physicians

Breast Cancer Drug Wins Approval Despite Rejection by Agency Advisors

Trump Pardon Sought for Clancy; Sen. Marshall's Medical Debt Suits; Lasker Winners

An Appeals Court Is Considering a Push to Restrict Most Common Abortion Method

Ectopic Pregnancy Deaths Have Nearly Doubled. It's Worse in Abortion-Ban States.

Residency Software Developer Sues Doctor Who Helped Launch a Competing Product

Bipartisan Campaign Pledges $100M to Cut U.S. Maternal Mortality Rate in Half

Recommended News For You

AACR: American Association for Cancer Research

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Cancer detection recovered following pandemic disruptions

Prostate cancer death risk is higher in late teens and early 20s weight gain.

Are ultramarathon runners really at increased risk of bowel cancer?

Recommended Articles For You

Tumor Neighborhoods and Therapy Response: Clinical and Mechanistic Insights

Demystifying Lymphocytes: Everything You Need to Know

Beyond the Blood: Expanding CAR T-Cell Therapy to Solid Tumors- A New Era of Precision Oncology

Clinical Methods in Hematology and Quality Improvement

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.